1. Home
  2. FPI vs OMER Comparison

FPI vs OMER Comparison

Compare FPI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FPI
  • OMER
  • Stock Information
  • Founded
  • FPI 2013
  • OMER 1994
  • Country
  • FPI United States
  • OMER United States
  • Employees
  • FPI N/A
  • OMER N/A
  • Industry
  • FPI Real Estate Investment Trusts
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • FPI Real Estate
  • OMER Health Care
  • Exchange
  • FPI Nasdaq
  • OMER Nasdaq
  • Market Cap
  • FPI 516.0M
  • OMER 188.1M
  • IPO Year
  • FPI 2014
  • OMER 2009
  • Fundamental
  • Price
  • FPI $11.08
  • OMER $3.65
  • Analyst Decision
  • FPI
  • OMER Strong Buy
  • Analyst Count
  • FPI 0
  • OMER 5
  • Target Price
  • FPI N/A
  • OMER $18.00
  • AVG Volume (30 Days)
  • FPI 466.0K
  • OMER 928.7K
  • Earning Date
  • FPI 07-23-2025
  • OMER 08-06-2025
  • Dividend Yield
  • FPI 2.17%
  • OMER N/A
  • EPS Growth
  • FPI 104.48
  • OMER N/A
  • EPS
  • FPI 1.09
  • OMER N/A
  • Revenue
  • FPI $56,535,000.00
  • OMER N/A
  • Revenue This Year
  • FPI N/A
  • OMER N/A
  • Revenue Next Year
  • FPI N/A
  • OMER $468.75
  • P/E Ratio
  • FPI $10.19
  • OMER N/A
  • Revenue Growth
  • FPI N/A
  • OMER N/A
  • 52 Week Low
  • FPI $9.66
  • OMER $2.95
  • 52 Week High
  • FPI $12.87
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • FPI 42.06
  • OMER 54.74
  • Support Level
  • FPI $11.43
  • OMER $3.00
  • Resistance Level
  • FPI $11.69
  • OMER $3.25
  • Average True Range (ATR)
  • FPI 0.17
  • OMER 0.24
  • MACD
  • FPI -0.07
  • OMER 0.10
  • Stochastic Oscillator
  • FPI 15.38
  • OMER 83.33

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: